ClinicalTrials.gg
Active, not recruitingNCT07940257Updated Nov 16, 2026

Study of Furmonertinib as Follow-Up Treatment After Surgery for Early-Stage EGFR-Positive Lung Cancer: Real-World Observation

An observational study in NSCLC (Non-small Cell Lung Cancer), EGFR Activating Mutation and Early Stage Lung Non-Small Cell Carcinoma, sponsored by The Fourth Affiliated Hospital of Zhejiang University School of Medicine. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by The Fourth Affiliated Hospital of Zhejiang University School of Medicine · Observational

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
120
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,880 studies in Carcinoma, Non-Small-Cell Lung with a site in China — 763 open to participants now, 987 under way, 203 of them phase 3. Carcinoma, Non-Small-Cell Lung · China.

Enrollment
180th of 287
120 · median 200
Started
2026
with 190 others
Observational
287 of 1,880
114 open now
Primary completion
2028-09
later than 795 of 986 live
Registered
1,880th of 1,880
by date

Among the 1,880 studies in Carcinoma, Non-Small-Cell Lung with a site in China, this one is the 180th largest by enrollment of the 287 observational ones that give a count, is one of 191 that started in 2026, is one of 287 observational ones, reaches primary completion later than 795 of the 986 other live ones, and was the 1,880th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

763 of the 1,880 studies in Carcinoma, Non-Small-Cell Lung with a site in China are open now. Recruiting first, the newest first:

758 more — sign in →

All 763 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,880 studies in Carcinoma, Non-Small-Cell Lung with a site in China, or all of them as a file.
02

Study summary

Purpose of This Observational Study

This study aims to understand the real-world effectiveness of furmonertinib for patients with stage IA2 (high-risk) to IB, EGFR mutation-positive non-small cell lung cancer (NSCLC) who have undergone curative surgical resection and carry high risk factors for recurrence, and to evaluate the safety of the drug in this population. It is designed to answer the following key questions:

What is the 3-year disease-free survival rate for these early-stage lung cancer patients who take furmonertinib after surgery? What potential health issues may participants experience while taking furmonertinib? What are the 2-year and 3-year overall survival rates, and overall disease-free survival outcomes for patients taking furmonertinib after surgery? This study will not change participants' regular clinical treatment plans. We will only observe and record treatment and follow-up data of patients receiving furmonertinib adjuvant therapy in real clinical settings. The furmonertinib dosage is 80mg taken orally once daily, treatment duration follows actual clinical arrangements, and the core observation period is 3 years.

03

Conditions studied

  • NSCLC (Non-small Cell Lung Cancer)
  • EGFR Activating Mutation
  • Early Stage Lung Non-Small Cell Carcinoma

Keywords

  • furmonertinib
  • postoperative treatment
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This study plans to enroll approximately 120 patients with completely resected, stage IA2 (high-risk) to IB EGFR mutation-positive non-small cell lung cancer (NSCLC) who receive furmonertinib 80mg once daily as adjuvant therapy in real-world clinical settings. All enrolled patients will be followed up for a core period of 3 years post-surgery to collect efficacy and safety data. Eligible patients are those who meet all inclusion criteria and have no exclusion criteria as specified in the study protocol.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 to 75 years old, regardless of gender;
  • Have undergone curative resection for lung cancer, and have not received anti-tumor therapies including radiotherapy, chemotherapy, targeted therapy, or immunotherapy within 5 years before surgery; *Definition of curative resection: 1) Negative resection margins, including bronchi, arteries, veins, peribronchial tissues, and peritumoral tissues; 2) Systematic or specific lymph node dissection performed, with at least 6 lymph node stations sampled, including 3 stations of intrapulmonary (lobar, interlobar, or segmental) and/or hilar lymph nodes (N1) and 3 stations of mediastinal lymph nodes (N2, station 7 must be included); 3) No extranodal invasion in resected mediastinal lymph nodes or marginal lymph nodes of the resected lobe; 4) Microscopically negative highest dissected lymph node.
  • Confirmed EGFR sensitive mutation-positive (exon 19 deletion and/or exon 21 L858R mutation, with or without other EGFR mutations), verified by tumor tissue analysis;
  • diagnosed as stage IA2-IB non-small cell lung cancer (NSCLC) according to the 9th edition of IASLC TNM staging system;
  • Patients with stage IA2 disease have at least one high-risk factor for recurrence, including poorly differentiated tumor, vascular invasion, visceral pleural invasion, pathological subtype containing micropapillary/solid components or complex glandular structure, or spread through air spaces (STAS);
  • Adequate organ function: (1) Absolute white blood cell count ≥ 2000/mm³ (2) (ANC) ≥ 1000/mm³ (3) count ≥ 100000/mm³ (4) ≥ 9g/dL (Note: Patients should not receive blood transfusion or growth factor support for neutropenia, thrombocytopenia, or hemoglobin below the study threshold within 14 days before blood sample collection) (5) Endogenous rate ≥ 60 mL/min (calculated by 24-hour urinary creatinine measurement or Cockcroft-Gault formula) (6) Total ≤ 1.5 × (ULN) (Patients with Gilbert syndrome can be enrolled if total bilirubin \< 3 × ULN) (7) (AST) and alanine aminotransferase (ALT) ≤ 3 × ULN
  • Subjects must understand and sign the form.

Exclusion criteria

Exclusion Criteria:

  • Diagnosed with small cell lung cancer, or NSCLC with mixed pathological components containing small cell elements;
  • History of other malignant tumors within 5 years, or concurrent other malignant tumors (except carcinoma in situ);
  • Concomitant presence of other actionable driver gene alterations (including ALK fusion, ROS1 fusion, RET rearrangement, BRAF mutation, NTRK fusion, MET mutation, KRAS mutation, etc.; mutations in TP53, RB1 and other non-actionable genes are not excluded);
  • Pregnant or lactating women;
  • Received strong inhibitors within 7 days before the first dose, or strong CYP3A4 inducers within 21 days before the first dose; received traditional Chinese medicine (TCM) and TCM preparations indicated for anti-tumor use, TCM for tumor treatment, or other anti-tumor active drugs within 14 days before the first dose;
  • Severe or uncontrolled systemic diseases requiring treatment, which are deemed unsuitable for study participation by the investigator, including hypertension, diabetes mellitus, chronic heart failure ( class III-IV), unstable angina pectoris, myocardial infarction within 1 year, active bleeding, etc.; (including all HBsAg-positive patients), (positive anti-HCV antibody), or (HIV) infection; active infection requiring intravenous antimicrobial therapy;
  • Severe gastrointestinal dysfunction that may affect the intake, transport, or absorption of the study drug, such as inability to take oral medications, intractable nausea and vomiting, history of extensive gastrointestinal resection, etc.;
  • Meet any of the following cardiac assessment criteria: interval (QTc) > 470 ms at rest, calculated by Fridericia's formula; Any abnormality in rhythm, conduction, or morphology on resting (ECG), such as complete left bundle branch block, second- or third-degree atrioventricular block, etc.; Any factor that increases the risk of QTc prolongation or arrhythmic events, such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, unexplained sudden death of first-degree relatives under 40 years old, or concomitant use of any medication known to prolong QT interval that cannot be discontinued;
  • History of interstitial lung disease (ILD), drug-induced interstitial lung disease, radiation pneumonitis requiring treatment, or patients with clinical manifestations suspicious for interstitial lung disease;
  • Known or suspected to furmonertinib or any of its formulation;
  • Known mental illness or substance abuse;
  • Received within 30 days before the first dose of the study drug, including but not limited to mumps, rubella, measles, varicella/zoster, yellow fever, rabies, BCG, and typhoid vaccines. Inactivated viral vaccines are allowed;
  • Other conditions where the investigator deems the patient unable or unsuitable to participate in the study due to inability to comply with study procedures, restrictions, and requirements.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
120 participants (actual)
Target follow-up
3 Years
Patient registry
Yes

Interventions

  • The furmonertinib dosage is 80mg taken orally once daily, treatment duration follows actual clinical arrangements, and the core observation period is 3 years.

06

What researchers measure

Primary outcomes

  1. 3-year disease-free survival (3-year DFS) rate,Unit:Percentage (%)

    DFS is defined as the time from the initiation of furmonertinib adjuvant therapy to radiologically confirmed tumor recurrence or death from any cause. This index measures the proportion of patients remaining disease-free after 3 years of follow-up, with tumor recurrence assessed per RECIST version 1.1 criteria

    Time frame: From initiation of furmonertinib adjuvant therapy up to 3 years of follow-up

Secondary outcomes

  1. 2-year disease-free survival (2-year DFS) rate,Unit:Percentage (%)

    DFS is defined as the time from the initiation of furmonertinib adjuvant therapy to radiologically confirmed tumor recurrence or death from any cause. This index measures the proportion of patients remaining disease-free after 2 years of follow-up, with tumor recurrence assessed per RECIST version 1.1 criteria

    Time frame: From initiation of furmonertinib adjuvant therapy up to 2 years of follow-up

  2. 2-year Overall Survival(2-year OS),Unit:Percentage(%)

    OS is defined as the time from the initiation of furmonertinib adjuvant therapy to death from any cause. This index measures the proportion of patients alive after 2 years of follow-up

    Time frame: From initiation of furmonertinib adjuvant therapy up to 2 years of follow-up

  3. 3-year Overall Survival(3-year OS),Unit:Percentage(%)

    OS is defined as the time from the initiation of furmonertinib adjuvant therapy to death from any cause. This index measures the proportion of patients alive after 3 years of follow-up

    Time frame: From initiation of furmonertinib adjuvant therapy up to 3 years of follow-up

  4. Overall Median Disease-Free Survival(Median DFS),Unit:Month

    DFS is defined as the time from the initiation of furmonertinib adjuvant therapy to radiologically confirmed tumor recurrence or death from any cause. This index reports the median DFS of the entire study population, with tumor recurrence assessed per RECIST version 1.1 criteria

    Time frame: From initiation of furmonertinib adjuvant therapy up to 3 years of follow-up

  5. Incidence of all-grade furmonertinib treatment-related adverse events,Unit:Percentage(%)

    Adverse events are collected from treatment initiation to 30 days after treatment completion, and graded per the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0

    Time frame: From initiation of furmonertinib adjuvant therapy up to 30 days after completion of study treatment

  6. Incidence of grade ≥3 furmonertinib treatment-related adverse events,Unit:Percentage(%)

    Adverse events are collected from treatment initiation to 30 days after treatment completion, and graded per the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0

    Time frame: From initiation of furmonertinib adjuvant therapy up to 30 days after completion of study treatment

07

Study locations

1 site
  • Fourth Affiliated Hospital, Zhejiang University School of Medicine (ZJU4H, Yiwu)
    Yiwu, Zhejiang 322000, China
08

References and documents

Individual participant data

Plan to share: Yes — Baseline characteristics: Age at surgery, sex, smoking pack-year history, ECOG performance status, relevant comorbidities (COPD, cardiovascular disease, etc.), surgical details (procedure type, lymph node dissection extent, margin status), pathological data (2025 UICC TNM stage, tumor size, histologic subtype, high-risk features including lymphovascular invasion, visceral pleural invasion, STAS), and biomarker results (EGFR mutation subtype, PD-L1 TPS/CPS level, pre-surgery CEA/CYFRA21-1 levels). Treatment exposure data: Furmonertinib initial dose, total treatment duration, all dose adjustment/discontinuation events and corresponding reasons, concurrent medications that may interact with EGFR-TKIs, and records of adjuvant chemotherapy/radiotherapy received before or during targeted therapy (if applicable). Clinical outcome data: Safety outcomes including all adverse events graded by CTCAE 5.0 criteria, onset time, correlation with furmonertinib assessment, intervention measures, and ev

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Sep 2028, 24 months after the start.

Of 356 non-industry observational studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 126. This study's planned 24 months is below that.

Counting every sponsor, half of 498 studies reached it within 55 months; a quarter within 35 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2026
First posted
Nov 16, 2026
StartActual
Sep 1, 2026
Primary completionEst.
Sep 1, 2028
CompletionEst.
Sep 1, 2031
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07940257
Lead sponsor
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Collaborators
Sichuan Cancer Hospital and Research Institute, Guizhou Provincial People's Hospital, First Affiliated Hospital of Gannan Medical University, Sichuan Academy of Medical Sciences
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Sep 1, 2026
Primary completion
Sep 1, 2028 (estimated)
Completion
Sep 1, 2031 (estimated)
Last update
Nov 16, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion